Trials / Conditions / Obstetric Labour, Premature

Obstetric Labour, Premature

11 registered clinical trials studyying Obstetric Labour, Premature.

Status	Trial	Sponsor	Phase
Terminated	A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm NCT02377466	GlaxoSmithKline	Phase 3
Completed	Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating NCT02292784	GlaxoSmithKline	Phase 3
Terminated	A Randomized Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban for Women in Spontaneous Pre NCT02292771	GlaxoSmithKline	Phase 3
Completed	Study to Investigate the Pharmacokinetics (PK), Safety and Tolerability of Retosiban in Healthy Japanese Women NCT02377414	GlaxoSmithKline	Phase 1
Completed	A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Retosiban (GSK221149) When Dosed With Efa NCT01867996	GlaxoSmithKline	Phase 1
Completed	This Study Will Investigate the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, With Moxif NCT01702376	GlaxoSmithKline	Phase 1
Completed	A Two Cohort Study to Look at the Metabolites of GSK221149, the Metabolism of GSK221149 Administered With a Hi NCT01627587	GlaxoSmithKline	Phase 1
Completed	The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor NCT00404768	GlaxoSmithKline	Phase 2
Completed	A First Time in Human Study in Healthy Male Volunteers for Compound GSK557296. NCT00549211	GlaxoSmithKline	Phase 1
Terminated	A Study To Assess The Pharmacokinetics Of Different Modified Release Formulations Of GSK221149 In Healthy Adul NCT00449709	GlaxoSmithKline	Phase 1
Completed	Absorption, Distribution, Metabolism And Excretion Study For GSK221149A NCT00457925	GlaxoSmithKline	Phase 1